+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Future of Smoking Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • PDF Icon


  • 80 Pages
  • February 2019
  • Region: Global
  • VPA Research
  • ID: 4749277
The global demand for Smoking Addiction treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Smoking Addiction pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Smoking Addiction pipeline companies from advancing their products into Phase 3 or Phase 4.

Smoking Addiction Report Description

The 2019 pipeline study on Smoking Addiction pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Smoking Addiction pipeline compounds.

The Smoking Addiction pipeline guide presents information on all active drugs currently being developed for Smoking Addiction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Smoking Addiction pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Smoking Addiction drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Smoking Addiction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Smoking Addiction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Smoking Addiction pipeline report includes
  • An overview of Smoking Addiction disease including symptoms, causes, diagnosis and available treatment options is provided.

  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

  • Phase wise count of Smoking Addiction pipeline

  • Company wise list of Smoking Addiction pipeline

  • Mechanism of Action wise Smoking Addiction pipeline

For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

  • Current status of development

  • Drug overview

  • Mechanism of Action

  • Pre-clinical and Clinical Trials/Results

  • Company Overview and Recent Developments

Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations

  • Get clear understanding of the entire Smoking Addiction pipeline, with details on active projects

  • Stay ahead of the competition through comprehensive knowledge of Smoking Addiction pipeline progress

  • Get in detail information of each product with updated information on each project along with key milestones

  • Gain clear insights into companies participating in Smoking Addiction pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

  • Get trial information for each pipeline product under development

  • Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Table of Contents

1.1 List of Tables1.2 List of Figures
2. Global Smoking Addiction Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. Executive Summary
3.1 Smoking Addiction Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Smoking Addiction pipeline, H1- 2019
3.5 Mechanism of Action wise Smoking Addiction Pipeline Candidates
4 Achieve Life Sciences Smoking Addiction Pipeline Details
4.1 Achieve Life Sciences Business Profile
4.2 Achieve Life Sciences Smoking Addiction Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 Amygdala Neurosciences Smoking Addiction Pipeline Details
5.1 Amygdala Neurosciences Business Profile
5.2 Amygdala Neurosciences Smoking Addiction Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 Antidote Therapeutics Smoking Addiction Pipeline Details
6.1 Antidote Therapeutics Business Profile
6.2 Antidote Therapeutics Smoking Addiction Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 Aradigm Corp Smoking Addiction Pipeline Details
7.1 Aradigm Corp Business Profile
7.2 Aradigm Corp Smoking Addiction Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 AstraZeneca Plc Smoking Addiction Pipeline Details
8.1 AstraZeneca Plc Business Profile
8.2 AstraZeneca Plc Smoking Addiction Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 Axim Biotechnologies Inc Smoking Addiction Pipeline Details
9.1 Axim Biotechnologies Inc Business Profile
9.2 Axim Biotechnologies Inc Smoking Addiction Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 Axsome Therapeutics Inc Smoking Addiction Pipeline Details
10.1 Axsome Therapeutics Inc Business Profile
10.2 Axsome Therapeutics Inc Smoking Addiction Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 Bionex Pharmaceuticals LLC Smoking Addiction Pipeline Details
11.1 Bionex Pharmaceuticals LLC Business Profile
11.2 Bionex Pharmaceuticals LLC Smoking Addiction Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 C4X Discovery Smoking Addiction Pipeline Details
12.1 C4X Discovery Business Profile
12.2 C4X Discovery Smoking Addiction Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 CV Sciences Smoking Addiction Pipeline Details
13.1 CV Sciences Business Profile
13.2 CV Sciences Smoking Addiction Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14 Embera NeuroTherapeutics Inc Smoking Addiction Pipeline Details
14.1 Embera NeuroTherapeutics Inc Business Profile
14.2 Embera NeuroTherapeutics Inc Smoking Addiction Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15 Euthymics Bioscience Inc Smoking Addiction Pipeline Details
15.1 Euthymics Bioscience Inc Business Profile
15.2 Euthymics Bioscience Inc Smoking Addiction Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16 Jeil Pharmaceutical Co Ltd Smoking Addiction Pipeline Details
16.1 Jeil Pharmaceutical Co Ltd Business Profile
16.2 Jeil Pharmaceutical Co Ltd Smoking Addiction Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17 Lotus Pharmaceutical Co Ltd Smoking Addiction Pipeline Details
17.1 Lotus Pharmaceutical Co Ltd Business Profile
17.2 Lotus Pharmaceutical Co Ltd Smoking Addiction Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18 NAL Pharmaceuticals Ltd Smoking Addiction Pipeline Details
18.1 NAL Pharmaceuticals Ltd Business Profile
18.2 NAL Pharmaceuticals Ltd Smoking Addiction Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19 NFL Biosciences Smoking Addiction Pipeline Details
19.1 NFL Biosciences Business Profile
19.2 NFL Biosciences Smoking Addiction Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20 One World Cannabis Ltd Smoking Addiction Pipeline Details
20.1 One World Cannabis Ltd Business Profile
20.2 One World Cannabis Ltd Smoking Addiction Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
21 Pfizer Inc Smoking Addiction Pipeline Details
21.1 Pfizer Inc Business Profile
21.2 Pfizer Inc Smoking Addiction Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments
22 Selecta Biosciences Inc Smoking Addiction Pipeline Details
22.1 Selecta Biosciences Inc Business Profile
22.2 Selecta Biosciences Inc Smoking Addiction Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments
23 Tria Bioscience Corp Smoking Addiction Pipeline Details
23.1 Tria Bioscience Corp Business Profile
23.2 Tria Bioscience Corp Smoking Addiction Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments
24 Zynerba Pharmaceuticals Inc Smoking Addiction Pipeline Details
24.1 Zynerba Pharmaceuticals Inc Business Profile
24.2 Zynerba Pharmaceuticals Inc Smoking Addiction Drug Details
24.3 Drug Snapshot
24.3.1 Originator
24.3.2 Collaborator/Co-Developer
24.3.3 Route of Administration
24.3.4 Orphan Drug/Fast Track/Special Designation
24.3.5 Geography
24.3.6 Type of Molecular Entity
24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments
25. Latest Smoking Addiction Drug Pipeline Developments, 2019
26. Appendix
26.1 About Us
26.2 Sources and Methodology
26.3 Contact Information

Companies Mentioned

  • Achieve Life Sciences

  • Amygdala Neurosciences

  • Antidote Therapeutics

  • Aradigm Corp

  • AstraZeneca Plc

  • Axim Biotechnologies Inc

  • Axsome Therapeutics Inc

  • Bionex Pharmaceuticals LLC

  • C4X Discovery

  • CV Sciences

  • Embera NeuroTherapeutics Inc

  • Euthymics Bioscience Inc

  • Jeil Pharmaceutical Co Ltd

  • Lotus Pharmaceutical Co Ltd

  • NAL Pharmaceuticals Ltd

  • NFL Biosciences

  • One World Cannabis Ltd

  • Pfizer Inc

  • Selecta Biosciences Inc

  • Tria Bioscience Corp

  • Zynerba Pharmaceuticals Inc